This antibody detects Bcl-9-like protein at N-term. It is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist, this antibody will detect all four.
Cross-Reactivity (Details)
Species reactivity (tested):Human, mouse, rat
Purification
Affinity chromatography purified via peptide column
Immunogen
20 amino acid peptide near the amino terminus of human Bcl9L
Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with b-catenin, a target of the Wnt signaling pathway, and is required for enhanced ?-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating b-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.Synonyms: B-cell CLL/lymphoma 9-like protein, B-cell lymphoma 9-like protein, BCL9-like protein, BCL9L, DLNB11